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ABSTRACT 
Background. The nature of Multiple Organ Dysfunction Syndrome (MODS) after traumatic 
injury is evolving as resuscitation practices advance and more patients survive their injuries 
to reach critical care. We aimed to characterise contemporary MODS subtypes in trauma 
critical care at a population level. 
Methods. Adult patients admitted to major trauma centre critical care units were enrolled 
in this four-week point-prevalence study.  MODS was defined as daily total Sequential Organ 
Failure Assessment (SOFA) score >5.  Hierarchical clustering of SOFA scores over time was 
used to identify MODS subtypes.  
Results. 440 patients were enrolled, of which MODS developed in 245 (56%). MODS carried 
a high mortality (22% vs. 1%, p<0.001) and 24% of deaths occurred early, within the first 48 
hours after injury. Three patterns of MODS were identified, all present on admission. Cluster 
1 MODS resolved early with a median time to recovery of four days and a mortality of 14%. 
Cluster 2 had a delayed recovery (median 13 days) and mortality of 35%. Cluster 3 had a 
prolonged recovery (median 25 days) and high associated mortality of 46%. Multivariable 
analysis revealed distinct clinical associations for each form of MODS, with 24-hour 
crystalloid administration strongly associated with Cluster 1 (p<0.001); traumatic brain 
injury with Cluster 2 (p<0.01); and admission shock severity with Cluster 3 (p<0.01).  
Conclusions. Contemporary MODS has at least three distinct types based on patterns of 
severity and recovery.  Further characterisation of MODS subtypes and their underlying 
pathophysiology may lead to future opportunities for early stratification and targeted 
interventions.  
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INTRODUCTION  
Multiple Organ Dysfunction Syndrome (MODS) is common in critically injured trauma 
patients who survive the initial insult, and is associated with poor outcomes(1).  MODS is 
responsible for a large proportion of the healthcare resources associated with acute trauma 
care(2).  As early-phase management strategies such as damage control resuscitation have 
been introduced and more trauma patients are surviving to reach critical care the nature of 
MODS appears to be changing (3). Reports of differences in patterns of evolution, severity 
and outcome are challenging the previously accepted clinical concepts of ‘early and late 
onset’ or bimodal peaks of MODS (4-9).  Determining the incidence, patterns, and outcomes 
of MODS in the modern era may help to identify therapeutic opportunities and inform study 
design for future research. 
With more early survivors of severe injury, MODS remains a determinant of poor outcomes 
and a continued challenge for trauma systems (2, 7).  The pathophysiology of MODS is a 
subject of debate in the literature. Some of the uncertainty may be due to the existence of 
discrete forms of MODS with unique pathophysiologies.  Recent studies have described 
protracted forms of MODS associated with aging, immunosuppression, infection and 
catabolism (4, 10, 11).  The national incidence of these contemporary MODS subtypes, their 
resource utilization and associated outcomes are not known.  Characterizing these different 
MODS subtypes is important if progress is to be made in understanding their underlying 
pathophysiologies, in developing new diagnostic and therapeutic approaches, and for the 
design of clinical studies in which to test them. 
The overall aim of this study was to characterise contemporary MODS subtypes in trauma 
critical care at a population level. Our primary aim was to establish the overall incidence of 
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MODS, describe patterns of severity and recovery, and their associated outcomes. We 
specifically wished to examine different patterns of MODS onset and recovery.  Our 
subsequent aim was to describe admission characteristics associated with any identified 
MODS subtypes.  We conducted a point-prevalence study of patients admitted to critical 
care in major trauma centres in the United Kingdom. 
 
METHODS 
Study sites and participants 
England, Wales and Scotland have an organised system of regional trauma networks, each 
with a Major Trauma Centre (MTC) (Level One equivalent) designated to manage the most 
severely injured patients in a geographical region. In the UK, MTCs should adhere to trauma 
resuscitation guidelines from the National Institute of Clinical Excellence(12).  All MTCs were 
invited to participate and adult trauma patients (≥16 years) requiring admission to a critical 
care unit from 00:01h 1st June to 23.59h 30th June 2016 were eligible for inclusion. Study 
approval was provided by the NHS Research Ethics Committee (REC), Health Research 
Authority and Scotland REC A, ref: 15/SS/0170. Patients were enrolled into the study after 
admission to critical care, and informed consent was obtained from the patient or a 
consultee.  
 
Study procedures 
Procedures and training were provided via the Organ Dysfunction in Trauma (ORDIT) study 
webpages(13). Data on demographic characteristics, injury severity, admission physiology 
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and 24 hour resuscitation were recorded. Patients were reviewed daily in critical care until 
discharge or death.  
 
Definitions 
The presence and evolution of Multiple Organ Dysfunction Syndrome (MODS) was 
determined with Sequential Organ Failure Assessment (SOFA) scoring (14, 15).  SOFA was 
chosen for wide utilisation in international critical care.  It has been validated for use in 
trauma patients including studies applying it from day of admission (16)  and has a good 
balance of sensitivity and specificity in predicting unfavourable outcome after severe injury 
(14). SOFA scores were measured daily from admission as described in earlier critical care 
studies (16-18). MODS was defined as the occurrence of a total SOFA score greater than 
five, affecting two or more organs (1, 4, 19). Recovery was when the SOFA score fell and 
remained below six. Traumatic Brain Injury (TBI) was classified as a head abbreviated injury 
score (AIS) of greater than or equal to three.  Secondary outcomes were in-hospital 
mortality, ventilator days, critical care and hospital length of stay (LOS).   
 
Data analysis 
Data analysis was conducted using IBM SPSS Statistics (Version 21).  Categorical variables 
were analysed using Chi-squared or Fishers Exact tests. Continuous data was non-
parametric according to the Shapiro-Wilk tests and analysed with Mann-Whitney U and 
Kruskall Wallis tests. Multiple comparisons of individual pairs were analysed with Bonferroni 
corrections. Unsupervised hierarchical clustering was performed to define MODS cohorts 
using Morpheus online software (Broad Institute, MA). Previous clinical studies have utilised 
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hierarchical clustering analysis to classify patients within a population into discrete clusters 
or phenotypes on the basis of clinical data (18, 20, 21).  Raw total SOFA score data for each 
patient on each day 1-28 (or day of critical care discharge/death if earlier) were entered into 
the data matrix. A SOFA score of 0 was assigned on discharge from ICU (unless readmitted). 
In patients who died during the 28-day period, no score was allocated after the date of 
death.  These data were treated as missing in the clustering analysis and were excluded 
from all computations involving the rows within which they occurred. Heatmaps were 
generated using Euclidean distance between observations and complete linkage between 
clusters. Complete linkage has been reported to produce more meaningful separation 
between clusters than average linkage (22, 23) and standard Grubbs test was used to 
identify outliers (24). We chose the number of clusters by subjectively selecting a single 
threshold height that maintained reasonable sub-cluster sample size.  The sensitivity and 
specificity of the clusters ability to detect MODS on each day was used to determine serial 
Youden indices and reported as sensitivity + specificity −1.  
Multivariable logistic regression models were used to describe the association between 
admission or treatment variables and MODS. Variables with p<0.1 on univariate testing 
were entered into the regression analysis. Results are presented as Odds Ratios (OR) with 
95% Confidence Intervals (CI). The calibration and goodness of fit of the logistic regression 
models were evaluated using the chi squared Hosmer-Lemeshow (HL) test, and model 
discrimination was assessed using area under the receiver–operator characteristic (AUROC) 
curves. Correlations between crystalloid use and MODS are described using Spearman’s 
rank correlation coefficients. 
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RESULTS 
All 29 adult major trauma centres in England, Wales and Scotland participated in the study.  
In total 446 patients were admitted to critical care during the one-month period, of which 
six died within the first 24 hours from injury. Of the remaining 440 patients, 56% (245) 
developed MODS (Table 1). The onset of MODS was on the day of admission in the majority 
of patients (94%). The remainder developed MODS on day two (5%) or day three (1%).  Only 
two patients experienced a second episode of MODS, one at day seven and one at day 11. 
Average admission SOFA was 8.5 (95% CI 8.2-8.8), and severity peaked on day two at 8.8 
(95% CI 8.5-9.1). Respiratory and cardiovascular dysfunction were the greatest contributors 
to MODS (97% and 91% of patients), followed by central nervous systems (CNS) (88%). 
Coagulation dysfunction affected 58%, whilst liver and renal systems had the lowest 
incidence of dysfunction (37% and 27% respectively).   Organ dysfunction patterns were 
similar in patients with and without TBI (Table E1 and Figures E1-E2 in the online data 
supplement).  22% of patients with MODS died, compared to less than 1% of the no-MODS 
group (Table 1).  In the 310 (70%) patients without TBI, MODS mortality was 15% compared 
to <1% without MODS (Table E1).  The overall median time to death with MODS was six days 
(IQR 2-10) and 24% of all MODS deaths occurred within the first 48 hours.  For survivors, 
average time in MODS was 10 days (IQR 5-17).   In total, the 245 patients with MODS utilized 
2656 critical care bed days and 5872 hospital days.  
 
Hierarchical clustering analysis of daily SOFA scores identified three high-level clusters of 
different patient recovery patterns (Figure 1). Cluster 1 was the largest with 362 patients, of 
which 167 developed MODS (68% of all MODS patients). All 54 patients in Cluster 2 
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developed MODS (22%), as did the 24 patients in Cluster 3 (10%). Admission SOFA scores for 
patients in MODS were higher in Clusters 2 and 3 (Day 1 mean SOFA score: Cluster 1 7.7 vs. 
Cluster 2 8.9 p=0.002, vs. Cluster 3 10.9, p<0.001).  SOFA scores of MODS patients in Cluster 
1 immediately began improving and in survivors had fallen below MODS thresholds by day 
five.  SOFA scores initially worsened for patients in Clusters 2 and 3 before beginning to 
resolve from day three, not falling below admission levels until day five (Figure 2A). Patterns 
of recovery did not appear to be affected by the presence of TBI (Figure 2B).  MODS in 
Cluster 2 patients took longer to resolve (median 13 days, IQR 12-16), while Cluster 3 had a 
very protracted duration of organ dysfunction (median 25 days, IQR 19-28)(Figure 2C).   
 
MODS had resolved in 92% of patients (120/131) in Cluster 1 by day seven, and no patients 
in this cluster remained in MODS after 11 days.  MODS patients in Cluster 1 were best 
discriminated from those in Clusters 2 and 3 by their MODS status on day eight.  88% of 
patients still in MODS at day eight were in Clusters 2 or 3 (Sensitivity 99%, Specificity 93% 
for Clusters 2/3, Youden 0.91).  Day 18 was the best discriminator between patients in 
Clusters 2 and 3, and  79% of patients still in MODS at day 18 were in Cluster 3 (Sensitivity 
85%, Specificity 94% for being in Cluster 3, Youden 0.78).  
The different patient clusters also had differing outcome profiles.  Within Cluster 1 MODS 
patients had a 14% mortality, rising to 35% in Cluster 2 (p<0.001) and 46% in Cluster 3 
(p<0.001, Table 1). Critical care stay for patients in Cluster 3 was double that of those in 
Cluster 2 (Cluster 2 vs 3: 20 vs. 36 days, p<0.001) and hospital stay was almost 40% longer 
(Cluster 2 vs 3: 39 vs. 53 days, p=0.030) (Table 1).  
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We analysed admission characteristics associated with the development of MODS in each 
cluster.  Cluster 1 MODS was the only cluster where the development of MODS was not 
associated with injury severity (Table 2), despite high injury severity scores (median ISS 25, 
Table 1).   The Cluster 1 MODS group was most strongly associated with the volume of 
crystalloid administered within the first 24 hours (Odds Ratio 2.8, Table 2, Figure 2D).  
Cluster 2 contained the greatest proportion of patients with TBI (59%, Figure 2E) and brain 
injury was strongly associated with this cluster (Odds Ratio 15.8, Table 2). Patients in Cluster 
3 were the only MODS subtype who were shocked on arrival (median BD: 7.6mmol/l vs. 
0mmol/l in all other MODS clusters, p=0.004, Figure 2F).  Both admission base deficit and 
24-hour crystalloids were independently associated with the development of prolonged 
MODS in Cluster 3 (Odds Ratio 1.11, p=0.003; Odds Ratio 1.24, p=0.019), Table 2).  
 
We explored the potential effect of crystalloid by examining variation in practice across the 
study sites.  The median crystalloid administration in MODS patients varied across sites from 
1 to 5.2 litres whilst the incidence of MODS ranged from 8% to 100% (Figure 3A, Table E2).  
There was a strong correlation between individual site crystalloid use and the development 
of MODS in Cluster 1 (Spearman r0.65, p<0.001). A modest correlation was seen in Cluster 3 
(Spearman r0.56, p=0.001), but not for Cluster 2 (Spearman r0.15, p=0.424) (Figure 3B). 
Overall, MODS resolved in a shorter time for patients who received less than 1.5L of 
crystalloid in the first 24 hours compared to those receiving greater volumes (Figure 3C). By 
day eight from injury almost twice the proportion of patients who had received more than 
1.5L of crystalloid were still in MODS compared to those who had received 0-1.5L (≤1.5L vs. 
>1.5L: 19% vs. 36%, p=0.010).   Critical care stay was longer for patients with MODS 
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receiving greater than 1.5L of crystalloid in the first 24 hours (≤1.5L vs. >1.5L: 5 vs. 7 days, 
p<0.001, Table E3). 
 
DISCUSSION 
This was a national point-prevalence study of MODS after traumatic injury in the era of 
contemporary damage control resuscitation, neurocritical care and regional trauma 
systems. MODS was common in this critical care population and had a high associated 
mortality and resource utilization. 7,604 trauma patients were admitted to critical care units 
in England and Wales in 2016 (source: Trauma Audit & Research Network, 
https://www.tarn.ac.uk/).  Nationally we would therefore predict over 3300 trauma patients 
in critical care with MODS annually, requiring 33,000 critical care bed days, of which 750 will 
die. Survivors will require 63,750 hospital days and may suffer long-term impairment to 
physical and psychological outcomes (25). 
 
Overall outcomes appear to have improved for patients with MODS in comparison to 
previous studies. Our MODS mortality of 22% compares with 33 - 36% in a study from the 
Glue Grant consortium in the USA which examined temporal trends in patients with MODS 
between 2003 and 2010(2).   In our study there was a preponderance of cardiovascular 
dysfunction in the initial days after injury.  Given that 34% of deaths occurred in this 
timeframe, it may be that cardiovascular dysfunction is the major component of MODS in 
the damage control resuscitation era.   
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MODS in our trauma patients appeared to be present on the first day of admission and had 
at least three distinct recovery patterns, an early resolving form and two types of persistent 
MODS.  31 patients (7% of total) with Cluster 1 MODS had resolved within the first 48 hours, 
and this group would not have been included in other studies which define MODS as 
occurring after day 2.  In contrast, nearly a third of MODS patients in our study had a 
prolonged form of MODS (Cluster 2 or 3) taking a median of 15 days to resolve. Historically 
MODS has had a bimodal distribution with a second peak in incidence occurring between 
seven and 14 days after injury(26).  This second peak has been declining (9) and appears to 
have all but disappeared in contemporary MODS with only three patients in our study 
developing MODS after day three.  Contemporary MODS is characterized by respiratory, 
cardiovascular and haemostatic dysfunction.  Respiratory and cardiovascular dysfunction 
were nearly universal in our MODS patients, whereas older studies have described 
involvement of these organ systems at around 50%(2).    Patients with different recovery 
trajectories were indistinguishable on admission solely by examination of total or 
component SOFA scores, but there were differences in injury patterns, shock severity and 
early management associated with the subsequent development of these MODS subtypes.  
 
Crystalloid use in the first 24 hours from injury was the only clinical variable associated with 
the Cluster 1 early resolving MODS subtype.   Crystalloids are known to have 
proinflammatory effects on coagulation and the endothelium (27-29), and volume of 
administration is associated with increased organ injury such as ARDS and abdominal 
compartment syndrome.  Previous trauma studies report the link between organ 
dysfunction and large volumes of crystalloid in the first 12 or 24 hours following injury (30, 
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31). Current national trauma haemorrhage guidance reflects this, recommending that 
crystalloids are avoided during damage control resuscitation(32). It is likely therefore that 
the majority of crystalloid administration occurs on the critical care unit.  We only examined 
fluid use in the first 24 hours, but this effect may persist for some days, as time to resolution 
was almost double that of Cluster 1 patients without MODS. Further research is needed to 
explore causality in this relationship and identify optimal strategies for on-going volume 
replacement in these patients. 
TBI characterised the group of patients whose MODS tended to persist, with a delayed 
recovery between days eight and 18. Brain injury is thought to potentially confound the 
assessment of MODS and its resolution (14, 33).  In this study there is little to differentiate 
patients with and without MODS in terms of their severity or pattern of TBI.  However, 
patients with TBI and MODS appear to have a specific, separate clinical trajectory, not 
limited to the CNS component of the SOFA score alone.  Further investigation is required to 
determine whether this is due to extracranial effects of TBI or current management 
paradigms. For example endogenous or exogenous catecholamines have both been 
postulated as responsible for some of the observed effects (34-36).  The presence of MODS 
is known to worsen outcomes for those with severe TBI (37, 38), therefore research focusing 
on this specific group of patients may unlock underlying mechanisms and lead to real 
improvements for brain injured patients. 
 
Patients in Cluster 3 with the prolonged form of MODS were the smallest cohort but had the 
worst outcomes and consumed a disproportionate amount of critical care resources.  
Previous studies of an indolent, immunosuppressive dysfunction have focused on elderly 
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patients (39, 40), but we found no difference in age between MODS clusters.  Admission 
shock was only associated with the subsequent development of prolonged MODS found in 
Cluster 3.  There was a weaker association with crystalloid administration in this group than 
in Cluster 1, and there was no association with the volume of blood product administration.  
These suggest that the persistent MODS in patients in Cluster 3 may be due to an early 
response to the shocked state, and not a later consequence of resuscitation. Prolonged 
MODS may represent the contemporary form of classical multiple organ failure, driven by 
dysregulation of the inflammatory response to injury (41).  Developing biomarkers and 
stratification tools to identify these patients early in their clinical course may allow the 
development of new management strategies and therapeutic opportunities for MODS after 
injury.  
 
There are a number of limitations to this study.  While wide geographically, it was limited in 
its accrual period and the number of data-points captured for each patient.  In particular, 
we were not able to capture the number and nature of infectious episodes or other 
complications which may have contributed to prolonged MODS. We were also not able to 
assign cause of death which would provide insight into if and how MODS contributed to the 
deaths of each patient. In the hierarchical clustering analysis, the selection of the number of 
clusters to analyse was based on a determination of adequate cluster size for intergroup 
analyses.  Further subtypes may be identified from deeper analysis in larger cohorts of 
patients. Whilst the majority of deaths in the early resolving MODS group occurred within 
48 hours, the patterns of deaths for the differing clusters require further evaluation. SOFA 
scoring differs from other MODS scores (such as the Denver(42) or Goris scores(43)) as it 
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contain CNS and coagulation components, which may lead to differences in reported 
incidence of MODS (33) and may partly account for differences in proportion of MODS in 
this study. However the use of SOFA in severely injured and TBI populations has a good 
discriminative ability and balance of sensitivity and specificity in predicting unfavourable 
outcome for trauma patients (14, 44). In our multivariable analyses examining associations 
of clinical variables with the development of MODS, there is potential overlap between 
SOFA components as both admission (input) and later SOFA (output) variables, such as the 
GCS.  While GCS was associated with the overall development of MODS, this association was 
lost when analysing individual clusters and in Cluster 2 only was the anatomic presence of a 
head injury associated with MODS development.  We therefore believe the analysis 
provides a robust signal for the associations across each analysis. As an observational study 
however, we can only identify associations of clinical variables with MODS but are unable to 
determine causation. In Cluster 3 there are only 24 outcomes which may lead to model 
over-fit. Larger cohort studies are required to explore these smaller cohorts, and potential 
further sub-cluster divisions.  Finally, the multicentre nature of this study may mean 
differing treatment policies despite national guidance, therefore we our study represents 
clinically focused descriptors of MODS subtypes rather than ones driven by biology alone. 
MODS is still common in the era of damage control resuscitation and has an associated 
mortality and high resource utilization.  Contemporary MODS is now almost always present 
from admission, commonly involves cardiovascular dysfunction, and has subtypes with 
different patterns of recovery.  Patients who will develop persistent MODS are difficult to 
identify on admission from their clinical characteristics.  The development of tools for the 
early identification of these subtypes will require further research on their individual 
initiating mechanisms.     
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TABLE 1. ADMISSION CHARACTERISTICS, INJURIES AND OUTCOMES 
 ALL MODS 
Cluster 1             
No MODS 
Cluster 1      
MODS 
Cluster 2     
MODS 
Cluster 3      
MODS 
n 245 195 167 54 24 
Admission 
variables: 
     
Age 47 (29-65) 48 (29-63) 47 (29-68) 47 (28-60) 42 (28-57) 
Male (%) 185 (76) 140 (72) 122 (73) 43 (80) 20 (83) 
Blunt (%) 222 (91) 166 (85) 151 (90) 51 (94) 20 (83) 
First GCS 13 (6-15)* 14 (9-15) 14 (6-15) 12 (4-15) 14 (9-15) 
First SBP 125 (104-145) 127 (107-141) 125 (103-145) 125 (110-143) 128 (110-144) 
First SBP 
<90mmHg (%) 
23 (9) 11 (6) 19 (11) 2 (4) 2 (8) 
First BD (mEq/L) 0.1 (0.4-6.7)*  0 (-1.2-1.1) 0 (-1.1-5.1) 0 (-0.2-5.0)  7.5 (0.3-11.1) 
CSL L/24H 2.9 (2.0-4.5)* 1.2 (1.0-2.0) 3.0 (2.0-4.5) 2.3 (1.7-3.8) 3.7 (2.2-5.0) 
RBC units/24H 4 (2-7)* 3 (2-4) 4 (2-6) 4 (2-7) 4 (2-11) 
FFP units/24H 4 (2-8)* 3 (2-4) 4 (2-8) 4 (2-6) 4 (2-8) 
FFP:RBC ratio 0.5 (0-1.0) 0.1 (0-0.6) 0.6 (0-1.0) 0.5 (0-1.0) 0.5 (0-0.8) 
TBI (%) 99 (40)* 30 (15) 56 (34) 34 (63) 9 (38) 
ISS 25 (18-36)* 17 (9-26) 25 (16-33) 29 (25-43) 31 (19-45) 
APACHE II score 14 (10-20) 9 (6-13) 14 (10-19) 15 (10-22) 18 (11-24) 
Outcomes:      
Mortality (%) 54 (22) 1 (<1) 24 (14) 19 (35) 11 (46) 
Ventilator days 4 (2-11) 1 (1-2) 3 (1-5) 11 (10-15) 16 (12-24) 
CCLOS 11 (5-19) 3 (2-5) 7 (4-14) 20 (16-27) 36 (32-47) 
THLOS 26 (13-40) 9 (5-20) 22 (12-33) 39 (25-62) 53 (39-104) 
Median (IQR) or n(%). Abbreviations = GCS: Glasgow Coma Scale; SBP: Systolic Blood Pressure; BD: Base 
Deficit; CSL: Crystalloid; RBC: Red Blood Cells; FFP: Fresh Frozen Plasma; TBI: Traumatic Brain Injury; ISS: Injury 
Severity Score; APACHE II: Acute Physiology and Chronic Health Evaluation II; CCLOS: Critical Care Length of 
stay; THLOS: Total Hospital Length of stay. Only 21 patients (5%) received colloids. Median (IQR) for All, No 
MODs and Clusters 1-3 were 0 (0-0). *signifies variables p<0.100 entered into multivariable analysis 
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TABLE 2. MULTIVARIABLE ANALYSIS OF FACTORS ASSOCIATED WITH THE DEVELOPMENT 
OF MODS 
 
 All MODS  
CLUSTER 1 
MODS 
 
CLUSTER 2 
MODS 
 
CLUSTER 3 
MODS 
 
n 245  167  54  24  
Predictor OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
First GCS 1.06 (0.92-1.2) 0.374 1.02 (0.91-1.09) 0.960 0.93 (0.85-1.01) 0.091 - - 
First BD 1.04 (0.94-1.1) 0.408 1.02 (0.96-1.09) 0.424 0.99 (0.92-1.07) 0.851 1.1 (1.01-1.2) 0.003 
CSL  L/24H  3.0 (1.7-5.4) 0.000 1.3 (1.07-1.6) 0.009 0.99 (0.81-1.2) 0.928 1.2 (1.03-1.5) 0.019 
RBC u/24h 1.2 (0.98-1.5) 0.069 1.02 (0.91-1.1) 0.705 - - - - 
FFP u/24h 1.1 (0.73-1.8) 0.516 1.1 (0.86-1.4) 0.370 - - - - 
TBI 4.2 (0.39-46.8) 0.232 2.0 (0.66-6.1) 0.474 3.5 (1.5-7.8) 0.002 0.98 (0.35-2.06) 0.973 
ISS 1.06 (1.01-1.1) 0.007 1.01 (0.93-1.03) 0.513 1.03 (1.0-1.06) 0.015 1.03 (1.004-1.06) 0.036 
Data presented as Odds Ratio (95% Confidence Intervals) and p values. Variables <0.1 in univariate analysis of 
All MODS group vs. NoMODS, or comparisons between Clusters 1-3 were entered into multivariable models.   
Abbreviations = GCS: Glasgow Coma Scale; BD: Base Deficit; CSL: Crystalloid; RBC: Red Blood Cells; FFP: Fresh 
Frozen Plasma; u: units; TBI: Trauma Brain Injury; ISS: Injury Severity Score. All patients model: AUROC 0.91 
(95% CIs 0.85-0.97), Hosmer-Lemeshow test 8.9, p= 0.34; Cluster 1 model: AUROC 0.79 (0.61-0.88), Hosmer-
Lemeshow test 5.8 p= 0.66; Cluster 2 model: AUROC 0.73 (0.63-0.82), Hosmer-Lemeshow test 4.4 p= 0.81; 
Cluster 3 model: AUROC 0.80 (0.72-0.88), Hosmer-Lemeshow test 7.0 p= 0.53. 
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Figure 3   
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Figure legends 
Figure 1. Unsupervised hierarchical clustering of sequential organ failure assessment (SOFA) scores from admission to day 28. Shades of red 
within the heatmap indicate patients with MODS, defined as a SOFA score of ≥6. Patients discharged from critical care were assigned a score of 
0 (blue). Patients who died within 28 days had missing scores after the date of death (black). Dashed line indicates the level of dendrogram 
transection used for analysis 
Figure 2. A. Line graph shows mean (95% CI) SOFA scores by day of hospital admission for patients in Cluster 1 No MODS, Cluster 1 MODS, 
Cluster 2 MODS and Cluster 3 MODS. B. Line graph shows mean (95% CI) SOFA scores by day of hospital admission for patients with MODS 
without Traumatic Brain Injury (TBI), MODS with TBI, No MODS without TBI, No MODS with TBI. C. Box and whisker plots show time to 
resolution of MODS in survivors, defined as days from admission to first reaching a SOFA score <6. D. Box and whisker plots show 24 hour 
crystalloid per cluster. E. Bar graph shows proportion of patients with TBI (Head AIS≥3) per cluster. F. Box and whisker plots show admission 
base deficit per cluster. Data in figures C, D and F were analysed using Kruskall Wallis with multiple comparisons of selected cluster groups 
using Bonferroni correction. Cluster groups in figure E were compared using chi squared analysis.  ***p<0.010 
Figure 3. A. Bar graph shows % of patients who developed MODS per ORDIT site, ranked 0-100%. B. Scatter plot shows % of patients per site 
with MODS in Clusters 1, 2 and 3, plotted against median crystalloid (CSL) use per site. Correlation between All MODS and site CSL use: 
Spearman rho 0.66, p<0.001; Cluster 1 MODS: Spearman rho 0.65, p<0.001; Cluster 2 MODS: Spearman rho 0.15, p=0.42; Cluster 3 MODS: 
4 
 
Spearman rho 0.56, p<0.001. C. Bar graph shows % of patients remaining in MODS per day from injury within quartiles of initial 24 hour 
crystalloid administration.  
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TABLE E1. ADMISSION CHARACTERISTICS AND OUTCOMES FOR PATIENTS WITH AND WITHOUT TBI   
 
 
Median (IQR) unless otherwise specified. *p<0.050; **p<0.010 when comparing No MODS and MODS groups without and with TBI. Abbreviations = GCS: Glasgow Coma 
Scale; SBP: Systolic Blood Pressure; BD: Base Deficit; CSL: Crystalloid; RBC: Red Blood Cells; TBI: Traumatic Brain Injury; ISS: Injury Severity Score; APACHE II: Acute 
Physiology and Chronic Health Evaluation II; CCLOS: Critical Care Length of stay; THLOS: Total Hospital Length of stay.   
 
No TBI No MODS  No TBI MODS  TBI No MODS  TBI MODS  
 164 146 31 99 
Age 48 (27-62) 47 (30-59) 38 (24-63) 46 (28-65) 
Male (%) 114 (70) 111 (76) 25 (81) 74 (75) 
Blunt (%) 128 (78) 130 (89) 30 (97) 84 (85) 
First GCS 15 (9-15) 14 (7-15)* 13 (3-15) 14 (6-15) 
First SBP 121 (115-129) 119 (112-120) 132 (110-152) 127 (106-150) 
Admission BD (mEq/L) 0 (-1.3-0.8) 0 (-0.8-6.4)** 0 (-1.3-4.2) 0.3 (-0.3-5.7) 
CSL L/24H (L) 0.5 (0.2-1.3) 2.6 (1.5-3.8)** 0.6 (0.3-1) 2.8 (2.3-3.2)** 
RBC units/24H 3 (2-5) 4 (2-8)* 1 (0-3) 3 (2-5)** 
ISS 16 (9-26) 25 (13-30)** 24 (15-31) 29 (24-36)** 
APACHE II score 9 (6-12) 14 (10-16)** 13 (7-16) 16 (10-23)* 
Outcomes:     
Mortality (%) 1 (<1) 22 (15)** 0 32 (32)** 
Ventilator days 1 (0-1) 3 (0-9)** 0 (0-2) 5 (2-11)** 
CCLOS 3 (2-4) 9 (4-18)** 3 (2-5) 13 (6-21)** 
THLOS 9 (5-20) 22 (12-39)** 11 (4-23) 29 (20-44)** 
6 
 
TABLE E2. CHARACTERISTICS OF PATIENTS WITH MODS PER SITE  
Site N enrol % MODS % TBI Age First GCS First SBP ISS APACHE II N (%) mortality 
1 34 56% 32% 54 (21-67) 7 (4-13) 124 (92-126) 29 (16-43) 11 (9-14) 2 (11) 
3 9 78% 14% 49 (47-62) 13 (9-15) 115 (112-153) 29 (16-34) 19 (16-22) 0 
4 30 40% 17% 63 (56-72) 13 (4-15) 127 (112-136) 36 (27-45) 13 (8-24) 6 (50) 
5 6 50% 0% 61 (51-86) 8 (3-15) 129 (102-163) 14 (1-20) 14 (6-26) 1 (33) 
6 7 100% 57% 41 (26-50) 9 (5-14) 114 (95-144) 18 (8-38) 26 (22-28) 0 
7 11 64% 45% 55 (24-66) 9 (4-15) 130 (113-152) 38 (25-57) 17 (4-19) 1 (9) 
8 10 50% 0% 46 (31-66) 13 (8-15) 100 (53-134) 29 (12-35) 11 (9-19) 0  
9 19 42% 25% 39 (24-52) 12 (3-15) 106 (72-146) 39 (25-55) 15 (8-16) 1 (13) 
10 10 30% 0% 52 (51-87) 15 (4-15) 122 (98-160) 16 (9-30) 11 (9-13) 2 (67) 
11 14 93% 46% 30 (23-66) 7 (3-14) 123 (107-135) 43 (32-46) 10 (7-14) 2 (15) 
12 19 16% 0% 56 (26-74) 8 (7-14) 121 (108-153) 27 (16-38) 10 (6-28) 2 (33) 
13 16 81% 0% 56 (43-72) 11 (7-15) 126 (103-133) 25 (18-39) 19 (16-22) 2 (15) 
14 3 67% 0% 55 (36-73) 14 (14-15) 134 (130-137) 10 (9-10) 12 (6-18) 0 
15 39 74% 59% 37 (26-63) 9 (6-15) 122 (104-152) 29 (25-34) 11 (9-15) 4 (10) 
16 6 83% 0% 34 (28-48) 14 (10-15) 110 (95-139) 9 (9-25) 8 (5-19) 0 
17 12 8% 0% 18 15 88 29 12 0 
18 14 43% 33% 46 (41-77) 8 (3-15) 132 (128-142) 18 (8-28) 14 (10-26) 2 (33) 
19 24 46% 54% 64 (39-72) 11 (8-14) 130 (113-169) 23 (14-26) 16 (10-24) 5 (21) 
20 17 53% 78% 41 (29-50) 4 (3-10) 137 (80-154) 34 (26-45) 10 (7-18) 2 (22) 
21 36 53% 21% 50 (32-79) 6 (3-15) 129 (105-140) 19 (10-29) 17 (13-18) 3 (16) 
22 17 94% 47% 55 (33-70) 13 (3-15) 119 (84-140) 25 (12-34) 19 (14-25) 4 (24) 
23 18 67% 64% 49 (33-69) 10 (3-15) 145 (112-156) 25 (21-32) 14 (10-17) 5 (28) 
24 13 69% 56% 68 (48-80) 14 (7-15) 137 (119-165) 25 (19-27) 15 (12-20) 2 (22) 
25 3 33% 100% 16 3 124 25 7 0 
26 8 63% 80% 57 (34-67) 12 (4-14) 159 (113-179) 9 (4-34) 22 (16-29) 2 (40) 
27 33 36% 58% 50 (41-57) 15 (12-15) 121 (103-140) 14 (9-21) 13 (9-16) 3 (25) 
28 2 100% 100% 29 (17-40) 8 (8-8) 126 (143-149) 29 (20-38) 20 (19-21) 0 
29 9 89% 50% 55 (39-66) 10 (5-15) 123 (72-172) 18 (12-58) 17 (12-22) 3 (38) 
Average  15.6 59% 52% 48 (30-62) ᶧ 10 (4-14) ᶧ 124 (104-123) ᶧ 24 (16-34) ᶧ 14 (10-20) ᶧ 2 (23) 
7 
 
Data presented for patients who developed MODS. ᶧ Median (IQR). Abbreviations = TBI: Traumatic Brain Injury; GCS: Glasgow Coma Scale; SBP: Systolic Blood Pressure; ISS: Injury Severity Score; APACHE II: Acute 
Physiology and Chronic Health Evaluation II. ORDIT site 2 enrolled two patients, neither of which developed MODS and sites 17 and 25 only had one patient who developed MODS. 
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TABLE E3. ADMISSION CHARACTERISTICS AND OUTCOMES FOR PATIENTS WITH MODS IN QUARTILES OF CRYSTALLOID  
Crystalloid Volume <1.5L 1.5 - 2.6L 2.6 - 3.9L >3.9L 
  57 64 52 72 
Age 45 (31-65) 49 (30-62) 48 (32-68) 46 (28-57) 
Male (%) 42 (74) 47 (73) 42 (81) 50 (69) 
Blunt (%) 50 (88) 60 (94) 48 (92) 62 (85) 
First GCS 13 (5-15) 14 (6-15) 14 (5-14) 14 (7-15) 
First SBP 127 (110-145) 123 (94-137) 127 (104-142) 126 (103-149) 
Admission BD (mEq/L) 0 (-0.1-4.0) 0 (-0.4-6.9) 0.05 (-0.5-6.8) 2.1 (0.1-7.0) 
CSL L/24H (L) 0.25 (0-1) 2 (1.7-2.2) 2.9 (2.6-3.3) 5.5 (4.9-6.0)** 
RBC units/24H 4 (1-6) 5 (2-7) 4 (2-6) 5 (2-6) 
TBI (%) 26 (46) 25 (39) 21 (40) 27 (37) 
ISS 25 (13-30) 26 (17-33) 25 (18-38) 26 (19-32) 
APACHE II score 17 (10-18) 15 (11-22) 14 (10-18) 13 (9-21) 
Outcomes:     
Mortality (%) 9 (16) 21 (33) 10 (19) 14 (19) 
Ventilator days 3 (1-8) 3 (1-11) 4 (1-11) 5 (2-12) 
CCLOS 6 (3-12) 7 (4-16) 10 (4-20) 13 (6-20)** 
THLOS 23 (12-40) 25 (10-40) 25 (13-35) 33 (18-47) 
9 
 
Median (IQR) unless otherwise specified. **p<0.010 when comparing four groups, no comparisons reached p<0.05. Abbreviations = GCS: Glasgow Coma Scale; SBP: Systolic 
Blood Pressure; BD: Base Deficit; CSL: Crystalloid; RBC: Red Blood Cells; TBI: Traumatic Brain Injury; ISS: Injury Severity Score; APACHE II: Acute Physiology and Chronic 
Health Evaluation II; CCLOS: Critical Care Length of stay; THLOS: Total Hospital Length of stay. 
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Figure E2 
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ONLINE DATA SUPPLEMENT FIGURE LEGENDS 
Figure. E1. Organ SOFA scores in all patients. Line graphs show mean (95% CI) individual organ component SOFA scores for a. Respiratory, b. 
Cardiovascular, c. Central Nervous, d. Coagulation, e. Hepatic and f. Renal systems by day of hospital admission in patients within Cluster 1 (C1) 
No MODS, C1 MODS, Cluster 2 (C2) MODS and Cluster 3 (C3) MODS.   
Figure. E2. Organ SOFA scores in patients without TBI. Line graphs show mean (95% CI) individual organ component SOFA scores for a. 
Respiratory, b. Cardiovascular, c. Central Nervous, d. Coagulation, e. Hepatic and f. Renal systems by day of hospital admission in patients 
within C1 No MODS, C1 MODS, C2 MODS and C3 MODS.     
 
 
